A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Aptose Biosciences Inc.
APTOF
$144K
Mkt Cap
Aptose Biosciences Inc. (APTOF) has a market capitalization of $4M. It is classified as a small-cap stock.
Aptose Biosciences Inc. (APTOF) does not currently pay a regular dividend.
Aptose Biosciences Inc. (APTOF) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Aptose Biosciences Inc. (APTOF) generated $-36 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Aptose Biosciences Inc. (APTOF) reported earnings per share (EPS) of $-1091.40 in its most recent fiscal year.
The Ledger Terminal provides 5 years of financial data for Aptose Biosciences Inc. (APTOF), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Aptose Biosciences Inc. (APTOF) has a book value per share of $-53.40, based on its most recent annual SEC filing.
Aptose is a science-driven clinical stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and our head office is located in Toronto, Canada. Our Programs We are advancing oral targeted agents to treat life-threatening hematologic cancers that require immediate treatment. We have two clinical-stage oral kinase inhibitors under active development for the treatment of hematologic malignancies: tuspetinib (HM43239) and luxeptinib (CG-806). A third molecule (APTO-253) is not undergoing active clinical development and will not be discussed further.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -19M | - | - | -42M | -65M | -55M |
| EPS | $0.68 | $-1,091.40 | $-6,822.90 | $-204.00 | $-21.90 | $-20.10 |
| Free Cash Flow | 0 | -36M | -45M | -32M | -44M | -34M |
| ROIC | 0.0% | - | - | - | - | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.14 | -0.35 | 0.03 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 0 | - | - | - | - | - |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | - | - | -110.8% | -88.0% | -46.5% |
| Shares Outstanding | 3M | 0M | 0M | 1M | 3M | 3M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 29M | 46M | 25M | 33M | 15M | 7.4M |
| SG&A | 26M | 19M | 15M | 16M | 11M | 12M |
| EBIT | N/A | N/A | N/A | N/A | N/A | 0 |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -55M | -65M | -42M | N/A | N/A | -19M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/A | N/A | N/A | N/A | N/A | 0.0% |
| ROE | -46.5% | -88.0% | -110.8% | N/A | N/A | 0.0% |
| ROA | -43.7% | -79.2% | -82.0% | N/A | N/A | -304.3% |
| Cash Flow | ||||||
| Op. Cash Flow | -34M | -43M | -32M | -45M | -36M | -24M |
| Free Cash Flow | -34M | -44M | -32M | -45M | -36M | 0 |
| Owner Earnings | -55M | -56M | -38M | -48M | -37M | -25M |
| CapEx | 79K | 212K | 24K | 29K | 5K | 0 |
| Maint. CapEx | 152K | 150K | 120K | 88K | 32K | 22K |
| Growth CapEx | 0 | 62K | 0 | 0 | 0 | 0 |
| D&A | 152K | 150K | 120K | 88K | 32K | 22K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 21M | 13M | 5.2M | 3.7M | 1.1M | 492K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -121M | -79M | -46M | -17M | -12M | -1.2M |
| Cash & Equiv. | 117M | 39M | 37M | 9.3M | 6.2M | 1.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.01 | 0.01 | 0.03 | -0.35 | -0.14 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 119M | 74M | 38M | -2.9M | -4.5M | -19M |
| Total Assets | 126M | 83M | 51M | 13M | 10M | 6.3M |
| Total Liabilities | 7.3M | 8.3M | 13M | 16M | 15M | 26M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -357M | -423M | -464M | -516M | -541M | -559M |
| Working Capital | 118M | 74M | 37M | -3.4M | 5.1M | -3.3M |
| Current Assets | 125M | 82M | 50M | 12M | 9.5M | 3.8M |
| Current Liabilities | 6.8M | 8.2M | 12M | 15M | 4.5M | 7.1M |
| Per Share Data | ||||||
| EPS | -20.10 | -21.90 | -204.00 | -6,822.90 | -1,091.40 | 0.68 |
| Owner EPS | -20.19 | -18.90 | -71.86 | -568.06 | -435.69 | -9.69 |
| Book Value | 43.27 | 24.88 | 72.04 | -34.10 | -53.40 | -7.62 |
| Cash Flow/Share | -12.33 | -14.51 | -61.69 | -524.09 | -422.86 | -7.55 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 2.7M | 3.0M | 0.5M | 0.1M | 0.1M | 2.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | 2.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 43.2 | 24.8 | 1.1 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -0.7% | -2.4% | -74.6% | -23.6% | -195.8% | N/A |
| Market Cap | 5.1B | 1.8B | 43M | 189M | 18M | 4.0M |
| Avg. Price | 2,767.02 | 1,597.39 | 414.68 | 173.77 | 28.88 | 1.56 |
| Year-End Price | 1,867.50 | 616.50 | 211.50 | 74.10 | 7.20 | 1.56 |
Aptose Biosciences Inc. passes 0 of 9 quality checks, indicating weak fundamentals.